2025-03-04 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0) Executive Summary:**

Johnson & Johnson (JNJ), a multinational healthcare corporation, shows a cumulative return significantly lagging behind the S&P 500 (VOO) over the analyzed period.  While demonstrating consistent revenue and profitability, recent performance indicates a potential need for further investigation into growth drivers and market positioning relative to the broader market.

**1) Performance Comparison:**

Johnson & Johnson (JNJ) is a diversified healthcare company producing medical devices, pharmaceuticals, and consumer goods.

* **JNJ Cumulative Return:** 41.70%
* **VOO (S&P 500) Cumulative Return:** 116.17%
* **Return Difference:** -74.5%  (JNJ underperformed VOO by 74.5 percentage points.)
* **Relative Underperformance:** 21.0% (This means JNJ's underperformance relative to VOO is in the 21st percentile of its historical range of under/outperformance.)

**Alpha and Beta Analysis:**

The provided data shows inconsistent Alpha and Beta values over time, suggesting JNJ's performance is not consistently correlated with the market's overall performance. While some periods show positive alpha (outperformance), others show negative alpha and a fluctuating beta, highlighting the importance of considering the specific market context and company-specific factors. Notably, the market capitalization (Cap(B)) shows a general upward trend.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 277.4 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.2 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 305.9 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 339.0 |
| 2019-2021  | 28.0% | 8.0% | -43.0% | 0.4 | 377.8 |
| 2020-2022  | 17.0% | 8.0% | 9.0% | 0.4 | 400.4 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 366.0 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 348.4 |
| 2023-2025  | 3.0% | 8.0% | -54.0% | 0.2 | 400.7 |


**2) Recent Price Movement:**

* **Closing Price:** $165.02
* **Last Market Price:** $166.47 (a $1.45 increase)
* **5-Day Moving Average:** $164.33
* **20-Day Moving Average:** $157.04
* **60-Day Moving Average:** $149.46

The price is above all three moving averages, suggesting a short-term bullish trend. The recent increase of $1.45 from the previous close signals a potential short-term positive momentum.


**3) Technical Indicators & Expected Return:**

* **RSI:** 78.46 (Indicates overbought conditions, suggesting potential short-term price correction.)
* **PPO:** 0.43 (Positive value suggests bullish momentum, but needs further analysis.)
* **Delta_Previous_Relative_Divergence:** +3.8 (Short-term upward trend)

The significant price increase from the previous close ($1.45) reflects a noticeable upward price movement.  The expected return of -106.2% over the long term (2+ years) relative to the S&P 500 is concerning and indicates a substantial potential for underperformance unless significant changes in the company's trajectory occur.


**4) Recent Earnings Analysis:**

The earnings data shows some volatility in EPS and relatively stable revenue. Further analysis is needed to understand the drivers behind the EPS fluctuations.  The significant jump in EPS for the quarter ending October 27, 2023 requires investigation, for example, to check for any exceptional items.


| 날짜 | EPS | 매출 |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |


**5) Financial Information:**

Both revenue and profit margin remain relatively stable and high, reflecting the strength of JNJ's business.  ROE, however, shows some fluctuation, indicating variability in the efficiency of capital utilization.


**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |


**6) Overall Conclusion:**

JNJ demonstrates consistent revenue and profitability, yet significantly underperforms the S&P 500.  While short-term indicators suggest positive momentum, the high RSI, substantial negative long-term expected return relative to VOO, and the volatility in EPS and ROE raise concerns.  Further investigation is needed to understand the drivers behind the underperformance and to assess the long-term investment potential.  A deep dive into the October 2023 EPS surge is crucial.  Considering the company’s size and history, a deeper fundamental analysis, beyond the provided data, is recommended before making any investment decisions.
